Acetazolamide Sodium

CHEMBL1200814 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

244.2 g/mol

LogP

—

Phase

4

Parenteral administration is the reason the sodium salt of acetazolamide exists, supplying the same carbonic anhydrase inhibition when swallowing is not possible or when a faster onset is required. Situations calling for that route include acute glaucoma, raised intracranial pressure and selected states of fluid overload, all circumstances in which delay would matter. Sustained use carries the effects expected from the parent drug: urine output rises, and serum potassium may fall over a prolonged course. Choosing the injectable salt therefore changes the speed and route of delivery rather than the pharmacological target. The salt is recorded as C4H5N4NaO3S2 with a formula mass close to 244.2 g/mol.

The injectable sodium salt form of acetazolamide, used when oral administration is not possible or a faster onset of action is needed. It has the same carbonic anhydrase inhibiting properties as oral acetazolamide and is used in acute glaucoma, intracranial hypertension, and certain fluid-overload conditions. Like the oral form, it increases urine output and can lower potassium levels with prolonged use.

分子量

244.2000 g/mol

TPSA

127.00 Å²

治療領域

Ophthalmology Glaucoma Hypertension

作用機序

The injectable sodium salt acts by the same mechanism as oral acetazolamide: reversible inhibition of carbonic anhydrase, reducing aqueous humour formation in the eye and causing bicarbonate diuresis with a mild metabolic acidosis in the kidney.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

The injectable sodium salt acts by the same mechanism as oral acetazolamide: reversible inhibition of carbonic anhydrase, reducing aqueous humour formation in the eye and causing bicarbonate diuresis with a …

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]

InChI

InChI=1S/C4H6N4O3S2.Na/c1-2(9)6-3-7-8-4(12-3)13(5,10)11;/h1H3,(H3,5,6,7,9,10,11);/q;+1/p-1

Molecular Formula

C4H5N4NaO3S2

HBD / HBA

2 / 7

回転可能結合数

2

重原子数

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

The injectable sodium salt form of acetazolamide, used when oral administration is not possible or a faster onset of action is needed. It has the same carbonic anhydrase inhibiting properties as oral acetazolamide and is used in acute glaucoma, intracranial hypertension, and certain fluid-overload conditions. Like the oral form, it increases urine output and can lower potassium levels with prolonged use.

The injectable sodium salt acts by the same mechanism as oral acetazolamide: reversible inhibition of carbonic anhydrase, reducing aqueous humour formation in the eye and causing bicarbonate diuresis with a mild metabolic acidosis in the kidney.

Yes, Acetazolamide Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200814. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 13290219. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Acetazolamide Sodium PillFYIで

構造

クイックデータ

分子式: C4H5N4NaO3S2

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.